Q-omics provides the consensus-scored SNORA36B profile across patient tissues and cancer cell-line models. SNORA36B expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNORA36B is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SNORA36B RNA expression shows 4,619 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight UVM, LUSC, and KIRC as cancer lineages where SNORA36B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA36B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA36B survival associations across molecular data types. SNORA36B RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA36B RNA expression–survival associations across cancer types. High SNORA36B expression shows unfavorable associations in UVM, STAD, BRCA, KIRP, UCS and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNORA36B RNA expression.
This table summarizes SNORA36B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA36B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA36B shows lower tumor expression in KIRC and higher tumor expression in LUSC and LUAD. The LUSC box plot shows higher SNORA36B RNA expression in tumor versus normal tissue (log2 FC = +0.286, t-test p = .049).
This table shows molecular features associated with SNORA36B in patient tissues and cancer cell lines. In patient samples, SNORA36B shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
